[go: up one dir, main page]

DE60140200D1 - Ex vivo verfahren und zusammensetzungen zur nukleinsäureverabreichung - Google Patents

Ex vivo verfahren und zusammensetzungen zur nukleinsäureverabreichung

Info

Publication number
DE60140200D1
DE60140200D1 DE60140200T DE60140200T DE60140200D1 DE 60140200 D1 DE60140200 D1 DE 60140200D1 DE 60140200 T DE60140200 T DE 60140200T DE 60140200 T DE60140200 T DE 60140200T DE 60140200 D1 DE60140200 D1 DE 60140200D1
Authority
DE
Germany
Prior art keywords
compositions
methods
administration
vivo method
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60140200T
Other languages
English (en)
Inventor
Kevin J Donahue
Eduardo Marban
Koichi Nagata
John H Lawrence
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johns Hopkins University
Original Assignee
Johns Hopkins University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johns Hopkins University filed Critical Johns Hopkins University
Application granted granted Critical
Publication of DE60140200D1 publication Critical patent/DE60140200D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0016—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the nucleic acid is delivered as a 'naked' nucleic acid, i.e. not combined with an entity such as a cationic lipid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
DE60140200T 2000-10-13 2001-10-15 Ex vivo verfahren und zusammensetzungen zur nukleinsäureverabreichung Expired - Lifetime DE60140200D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24023100P 2000-10-13 2000-10-13
PCT/US2001/032274 WO2002030470A1 (en) 2000-10-13 2001-10-15 Methods and compositions for nucleic acid delivery

Publications (1)

Publication Number Publication Date
DE60140200D1 true DE60140200D1 (de) 2009-11-26

Family

ID=22905689

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60140200T Expired - Lifetime DE60140200D1 (de) 2000-10-13 2001-10-15 Ex vivo verfahren und zusammensetzungen zur nukleinsäureverabreichung

Country Status (8)

Country Link
US (1) US6992070B2 (de)
EP (1) EP1331950B1 (de)
JP (1) JP2004534719A (de)
AT (1) ATE445417T1 (de)
AU (1) AU2002214596A1 (de)
CA (1) CA2425835A1 (de)
DE (1) DE60140200D1 (de)
WO (1) WO2002030470A1 (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2421584C (en) * 2000-09-06 2013-12-31 Johns Hopkins University Gene therapy for cardiac arrythmias
US20090175790A1 (en) * 2000-09-06 2009-07-09 The Johns Hopkins University Cardiac arrhythmia treatment methods and biological pacemaker
DE60140200D1 (de) 2000-10-13 2009-11-26 Univ Johns Hopkins Ex vivo verfahren und zusammensetzungen zur nukleinsäureverabreichung
JP4279558B2 (ja) * 2001-04-27 2009-06-17 ジョンズ・ホプキンス・ユニバーシティ 生物学的ペースメーカー
US20050272650A1 (en) * 2004-02-17 2005-12-08 Mohapatra Shyam S Materials and methods for treatment of inflammatory and cell proliferation disorders
US20080214437A1 (en) * 2002-09-06 2008-09-04 Mohapatra Shyam S Methods and compositions for reducing activity of the atrial natriuretic peptide receptor and for treatment of diseases
AU2003299204A1 (en) * 2002-10-02 2004-04-23 The Johns Hopkins University Focal calcium channel modulation
EP1551980A4 (de) * 2002-10-09 2006-05-17 Pfizer Prod Inc Stabilisierte nackt-dna-zusammensetzungen
US7488713B2 (en) 2004-03-18 2009-02-10 University Of South Florida Cancer treatment using C-type natriuretic peptides
US7722596B2 (en) * 2004-02-26 2010-05-25 Osprey Medical, Inc. Regional cardiac tissue treatment
US20060148742A1 (en) * 2004-02-26 2006-07-06 Kaye David M Polynucleotide delivery to cardiac tissue
US20070203445A1 (en) * 2004-02-26 2007-08-30 V-Kardia Pty Ltd Isolating cardiac circulation
US8759317B2 (en) 2004-03-18 2014-06-24 University Of South Florida Method of treatment of cancer using guanosine 3′, 5′ cyclic monophosphate (cyclic GMP)
EP1838319B1 (de) 2005-01-07 2018-03-07 The Johns Hopkins University Pde5-inhibitor-zusammensetzungen und verfahren für die immuntherapie
US20080188480A1 (en) * 2005-02-22 2008-08-07 Cedars-Sinai Medical Center Use of Sildenafil, Vardenafil and Other 5-Phosphodiesterase Inhibitors to Enhance Permeability of the Abnormal Blood-Brain Barrier
JP2009511064A (ja) * 2005-10-14 2009-03-19 ザ ジョンズ ホプキンス ユニバーシティー 生物学的興奮性細胞
US7825092B2 (en) * 2006-08-08 2010-11-02 University Of South Florida Dendroaspis natriuretic peptide for treatment of cancer
EP2079739A2 (de) * 2006-10-04 2009-07-22 Pfizer Products Inc. Pyrido[4,3-d]pyrimidin-4(3h)-onderivate als kalziumrezeptorantagonisten
US8152786B2 (en) * 2006-11-07 2012-04-10 Osprey Medical, Inc. Collection catheter and kit
US20090047703A1 (en) * 2007-08-17 2009-02-19 University Of Maryland, Baltimore ERG-1 Peptides and Polynucleotides and Their Use in the Treatment and Diagnosis of Disease
KR20100129295A (ko) 2008-02-19 2010-12-08 셀라돈 코포레이션 심근 내 바이러스 벡터의 흡수를 개선시키기 위한 조성물
US9050400B2 (en) * 2008-08-12 2015-06-09 Osprey Medical, Inc. Remote sensing catheter system and methods
US20100041984A1 (en) * 2008-08-12 2010-02-18 James Edward Shapland Impedance sensing device and catheter system
US9295816B2 (en) * 2009-12-09 2016-03-29 Osprey Medical, Inc. Catheter with distal and proximal ports
US10184942B2 (en) 2011-03-17 2019-01-22 University Of South Florida Natriuretic peptide receptor as a biomarker for diagnosis and prognosis of cancer
US9211372B2 (en) 2011-08-11 2015-12-15 Osprey Medical, Inc. Systems and methods for limb treatment
CN103920161A (zh) * 2014-03-27 2014-07-16 浙江大学 一种在细胞膜微囊中高效装载药物的方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5516651A (en) * 1991-11-15 1996-05-14 The General Hospital Corporation Nucleic acids encoding calcitonin receptor and uses thereof
US6448235B1 (en) * 1994-07-11 2002-09-10 University Of Virginia Patent Foundation Method for treating restenosis with A2A adenosine receptor agonists
GB9423911D0 (en) * 1994-11-26 1995-01-11 Pfizer Ltd Therapeutic agents
WO1999018792A1 (en) * 1997-10-10 1999-04-22 Johns Hopkins University Gene delivery compositions and methods
US6237077B1 (en) 1997-10-13 2001-05-22 Idea Corporation Instruction template for efficient processing clustered branch instructions
WO1999031982A1 (en) * 1997-12-19 1999-07-01 The Trustees Of The University Of Pennsylvania Transvascular delivery of a composition to an extravascular tissue of a mammal
AU6501499A (en) * 1998-09-29 2000-04-17 Johns Hopkins University, The Inducible genetic suppression of cellular excitability
DE60140200D1 (de) 2000-10-13 2009-11-26 Univ Johns Hopkins Ex vivo verfahren und zusammensetzungen zur nukleinsäureverabreichung

Also Published As

Publication number Publication date
US20020094326A1 (en) 2002-07-18
WO2002030470A8 (en) 2004-04-08
US6992070B2 (en) 2006-01-31
WO2002030470A1 (en) 2002-04-18
JP2004534719A (ja) 2004-11-18
EP1331950B1 (de) 2009-10-14
EP1331950A1 (de) 2003-08-06
AU2002214596A1 (en) 2002-04-22
CA2425835A1 (en) 2002-04-18
ATE445417T1 (de) 2009-10-15
WO2002030470A9 (en) 2003-02-06

Similar Documents

Publication Publication Date Title
DE60140200D1 (de) Ex vivo verfahren und zusammensetzungen zur nukleinsäureverabreichung
Shi et al. Modulation of chondrocyte motility by tetrahedral DNA nanostructures
WO2020198509A3 (en) Modified oligonucleotides with increased stability
DE60030970D1 (de) Verfahren und zusammensetzungen für nichtvirale gentherapie zur behandlung von hyperproliferativen krankheiten
DE60238416D1 (de) Plasmaprotein-matritzes und verfahren zu ihrer herstellung
AR040396A1 (es) Citoquinas protectoras de tejidos para la proteccion, restauracion y mejoramiento de celulas, tejidos y organos receptivos
WO1998049300A3 (en) Truncated vegf-related proteins
WO2008054466A3 (en) Delivery of biologically active materials using core-shell tecto (dendritic polymers)
EP1248794A4 (de) Antisens-modulierung der smad7 expression
ATE277645T1 (de) Peptid-beschichtete implantate und verfahren zu ihrer herstellung
Damiati et al. An overview of RNA-based scaffolds for osteogenesis
DK1526840T3 (da) Nanopartikler til DNA administration til et målorgan
US11857598B2 (en) Self-replicating cell selective gene delivery compositions, methods, and uses thereof
WO2008098569A3 (de) Biologisch wirksame moleküle, insbesondere auf grundlage von pna und sirna, verfahren zu deren zellspezifischen aktivierung sowie applikationskit zur verabreichung
PT1175489E (pt) Oligonucleotidos contendo uma sequencia antisense estabilizada por uma estrutura secundaria e composicoes farmaceuticas contendo as mesmas
WO2006089340A3 (en) Polynucleotide delivery to cardiac tissue
EP1023005A4 (de) Verfahren zum beschichten von stents mit dna sowie zur in vivo expression von rekombinanten genen von mit dna beschichteten
WO2010019914A3 (en) Anti-arrhythmia agents, methods of their use, methods for their identification, and kits thereofre
ATE514718T1 (de) Peptabody für krebsbehandlung
MXPA02005069A (es) Agentes de enlace especificos para t3 y metodos para su uso.
ATE239749T1 (de) Phosphor-enthaltende dendrimere als transfektionsagente
ATE500840T1 (de) Verwendung von gilz-protein zur modulation einer antigenspezifischen immunantwort
ITMI20030860A1 (it) Metodo per l'inibizione selettiva del gene n-myc
ATE385252T1 (de) Verfahren zur herstellung von granulatförmigen zusammensetzungen
DE60114193D1 (de) Transfektionssystem

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: JOHNS HOPKINS UNIVERSITY, BALTIMORE, MD., US

R082 Change of representative

Ref document number: 1331950

Country of ref document: EP

Representative=s name: PATENT- UND RECHTSANWAELTE KRAUS & WEISERT, 80539